ICE-PAC : A phase II study of Avelumab + stereotactic ablative body radiosurgery (SABR) for metastatic castration-resistant prostate cancer (mCRPC). To assess radiographic progression-free survival (rPFS)

Male<br/>OnlyGender Male
Only

RecruitingStatus Recruiting

Multiple<Br/>Treatment TypesTypeMultiple
Treatment Types

TwoPhase Two

18+Age Over 18

Prostate<br/>CancersCancer LocationProstate
Cancers

Multiple treatment types,Radiotherapy,Systemic therapy | Urinary systemProstate

Trial Overview Read MoreRead more

This phase II trial is assessing the combination of an immunotherapy drug (Avelumab) and stereotactic ablative body radiotherapy (SABR) for the treatment of castrate-resistant prostate cancer.
 

This trial is treating patients with castrate-resistant prostate cancer.

This is a radiotherapy and systemic therapy trial.

You may be able to join this trial if:

  • Your cancer has spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A phase II study of Avelumab + stereotactic ablative body radiosurgery (SABR) for metastatic castration-resistant prostate cancer (mCRPC). To assess radiographic progression-free survival (rPFS)

Commercial Sponsor

Merck

Other Non-Commercial Sponsor

Monash Health

Summary

This is a non-randomised trial. Patients enrolled in this trial will receive a single fraction of 20 Gy to 1-2 metastases (bone and/or lymph node) with the location of sites selected at the discretion of the treating radiation oncologist. This will be followed by Avelumab commencing within 5 days +/- 3 days of SABR. After completing cycle 1 of Avelumab, patients will receive a second course of treatment with SABR to 1-2 different metastases for 5 days +/-3 days.

Recruiting Hospitals Read MoreRead more

Monash Health, Medical Oncology
Clayton
Genitourinary Research Study Coordinator
gu.oncresearch@monashhealth.org

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next